Skip to main content

Posts in the ‘Archive’ Category

Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica

Canterbury, UK – 19th March 2015 – Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces today that it has published positive Phase 2b clinical data for its novel TrkA kinase inhibitor CT327 in Acta Dermato-Venereologica, one of the pre-eminent international peer-review journals in dermatology. Read more »

Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology (AAD) Annual Meeting

– Phase 2b data demonstrates a 60% reduction in pruritus in psoriatic patients treated with CT327 – Data analysis also published in the Journal of the American Academy of Dermatology Canterbury, UK – 21 March 2014 – Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces that data ... Read more »

Creabilis Publishes New Data on Lack of Correlation between Pruritus Severity and Psoriasis Disease Severity in the Journal of the American Academy of Dermatology

Canterbury, UK – 4 March 2014 – Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces the publication of new results showing pruritus severity in psoriasis patients is not correlated with psoriasis disease severity in a letter to the Journal of the American Academy of Dermatology (JAAD). Read more »